Frames the sale as an aggressive re-allocation away from asymmetric downside, not cowardice: at 85x TTM sales with an unverified catalyst and a binary launch, the reward (+5.5%) is dwarfed by the gap risk (a bad Flight 14 headline can move the stock 10-20% before anyone can exit).
Rejects "waiting for evidence" as hoping — sell now into strength, hold cash, and re-enter only on a confirmed close above $156.92 on real volume; that is confirmation, not chasing.
Agrees the near-term risk/reward from the band middle is unattractive, but notes the intermediate trend isn't broken — price is above the 200 SMA, the 50 SMA has turned up, and the ~$60B net cash makes this a de-rating risk, not a solvency story.
Recommends a one-third to one-half trim to underweight now, keeping a smaller core sized so a move to the lower band is painful but not damaging, with a real stop below $143.30/$139.87 (not at $156.92, which is the re-entry trigger) and a laddered re-entry plan.
Supports the sell as capital preservation, not market timing: negative risk/reward, a binary catalyst, an $85.7B equity-funded balance sheet, and TTM FCF near -$19B all argue for cutting risk before Flight 14.
Explicitly rejects shorting (the ~$60B net cash and NASA backlog rule out a solvency thesis) and rejects chasing a breakout — wait for verified evidence (disclosed compute deal, durable Q3 print, or a sustained close above $156.92) before scaling back in gradually.
Thesis: Underweight SPCX at $148.68: cut to roughly half your standard allocation (deeper if oversized), do not add ahead of Starship Flight 14, and if flat, stay flat — no initiation and no short given the ~$60B net-cash balance sheet. Both sides agree SPCX is a great company; the fight was over the price of admission, and the bear won decisively on price, funding, and catalyst quality — not the franchise. The bull's growth evidence is uncontested (Q2'26 revenue $7.81B, +92% YoY, +66% sequential, positive EBITDA of $2.96B, $14.3B of prepayments, $5.92B NASA backlog through 2030), and that franchise strength plus ~$60B net cash is why this stops at Underweight rather than Sell. But nearly every price-side number fell to the bear: ~$1.96T market cap is ~85x trailing sales; GAAP operating income and net income are both negative; TTM FCF is ~-$19B; Q2 capex of $19.2B exceeded all of FY2024; and the net-cash position exists only via $85.7B of new equity — about four quarters of runway at the Q2 burn, with another large raise plausible within a year. Catalyst quality failed scrutiny: the $1.11B/month compute deal is unverified with no named customer, deferred revenue covers ~5.5 months of revenue (not the ~18 months claimed), the NASA modification is a rounding error at this scale, and Flight 14 is binary with no Falcon 9 rideshare buffer, with Rocket Lab reportedly positioned to catch any surrendered book.
Action: for any retained core, a close below the 200-day at $143.30 is an early warning and a decisive high-volume break below $139.87 cuts to minimal/zero; $156.92 is the re-entry trigger, not a stop. Rebuild only on verified evidence — a disclosed ~$1.11B/month compute deal, a durable Q3'26 print (sequential growth with gross margin near Q2 levels), or a sustained close above $156.92 on ~335M-share volume — and re-run the full thesis after Q3'26 earnings, which is the stated test of whether +92% growth was a step-change or a one-off.